Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial-Reference-Cited by-同舟云学术

Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial

Published:2023-05 Issue:10390 Volume:401 Page:1786-1797
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Verrastro Ornella,Panunzi Simona,Castagneto-Gissey Lidia,De Gaetano Andrea,Lembo Erminia,Capristo Esmeralda,Guidone Caterina,Angelini Giulia,Pennestrì Francesco,Sessa Luca,Vecchio Fabio Maria,Riccardi Laura,Zocco Maria Assunta,Boskoski Ivo,Casella-Mariolo James R,Marini Pierluigi,Pompili Maurizio,Casella Giovanni,Fiori Enrico,Rubino Francesco,Bornstein Stefan R,Raffaelli Marco,Mingrone Geltrude

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis;Younossi;J Hepatol,2019

2. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis;Quek;Lancet Gastroenterol Hepatol,2023

3. Design and validation of a histological scoring system for nonalcoholic fatty liver disease;Kleiner;Hepatology,2005

4. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease;Estes;Hepatology,2018

5. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis;Vilar-Gomez;Gastroenterology,2015

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Integrator complex subunit 6 promotes hepatocellular steatosis via β-catenin-PPARγ axis;Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids;2024-10

3. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

4. Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches;Cureus;2024-09-10

5. Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic Drugs;Diabetes Technology & Therapeutics;2024-09-01